Tarsus Pharmaceuticals, Inc. last reported quarterly results on Nov 3, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $194.6 million (+63.9% year over year) and diluted EPS of -$14.40. It usually reports 34–54 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 22, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Feb 23, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 34–54 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 3, 2026
34 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
195
+63.9%
|
-668
-5210.6%
|
-14.40
-4700.0%
|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
174
+69.4%
|
-19
+8.8%
|
-0.43
+10.4%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
162
+106.9%
|
-7
+72.3%
|
-0.16
+75.0%
|
|
Feb 23, 2026
54 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
152
+128.4%
|
-8
+63.8%
|
-0.20
+67.3%
|
|
Nov 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
119
+146.7%
|
-13
+46.3%
|
-0.30
+50.8%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
103
+151.5%
|
-20
+38.9%
|
-0.48
+45.5%
|
|
May 1, 2025
31 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
78
+183.7%
|
-25
+29.7%
|
-0.64
+36.6%
|
|
Feb 25, 2025
56 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
66
+407.9%
|
-23
+44.8%
|
-0.60
+52.4%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TARS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Irvine, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1819790
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.